SIXTH AMENDMENT AGREEMENTSixth Amendment Agreement • November 6th, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances)
This Sixth Amendment Agreement, effective as of August 18, 2006 (the “Effective Date”), is entered into by and between the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, having offices at Flemingovo nam. 2, 166 10 Praha 6, Czech Republic (“IOCB”); and the K. U. Leuven Research and Development (representing the REGA Institute for Medical Research, Leuven), having offices at Groot Begijnhof 59, B-3000 Leuven, Belgium (“REGA”) (IOCB and REGA hereinafter collectively referred to as “IOCB/REGA”) on one side and Gilead Sciences, Inc., a Delaware, USA corporation, having offices at 333 Lakeside Drive, Foster City, California 94404, U.S.A. (“Gilead”), on the other side. In this Sixth Amendment Agreement IOCB, REGA and GILEAD are sometimes referred to individually as a “Party” and collectively as the “Parties”.
RESTRICTED STOCK AWARD AGREEMENT Restricted Stock Award #<<Restricted Shares>>«NUM»Restricted Stock Award Agreement • November 6th, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
GILEAD SCIENCES, INC. (the “Company”), pursuant to its 2004 Equity Incentive Plan, as amended (the “Plan”) and this Restricted Stock Award Agreement (the “Agreement”), has this day granted to you, the grantee named above (“Grantee”), an award of Restricted Stock (“Restricted Stock Award”) consisting of shares of the common stock of the Company (the “Common Stock”), subject to the terms and conditions set forth in this Agreement and otherwise provided in the Plan. Any terms not defined herein shall have the meaning set forth in the Plan.
DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN GILEAD SCIENCES, INC. AND F. HOFFMANN-LA ROCHE LTD AND HOFFMANN-LA ROCHE INC. SEPTEMBER 27, 1996Development and License Agreement • November 6th, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
THIS DEVELOPMENT AND LICENSE AGREEMENT (the “AGREEMENT”), dated as of September 27, 1996 (the “EFFECTIVE DATE”), is made by and between GILEAD SCIENCES, INC., a Delaware corporation (“GILEAD”), on the one hand, and F. HOFFMANN-LA ROCHE LTD, a corporation organized under the laws of Switzerland, and HOFFMANN-LA ROCHE INC, a corporation organized under the laws of New Jersey, on the other hand (collectively, “ROCHE”).
AMENDED AND RESTATED COLLABORATION AGREEMENT by and among GILEAD SCIENCES, INC., GILEAD HOLDINGS, LLC, BRISTOL-MYERS SQUIBB COMPANY, E.R. SQUIBB & SONS, L.L.C., and BRISTOL-MYERS SQUIBB & GILEAD SCIENCES, LLC Dated as of September 28, 2006Collaboration Agreement • November 6th, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
Princeton, N.J. and Foster City, Calif., September 28, 2006 – Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement to commercialize ATRIPLATM (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada for the treatment of HIV-1 infection in adults, subject to the approval of the product by Health Canada. ATRIPLA is the first once-daily single tablet regimen (STR) for HIV intended as a stand-alone therapy or in combination with other antiretrovirals. ATRIPLA received approval from the U.S. Food & Drug Administration on July 12, 2006.
AGREEMENT AND PLAN OF MERGER BY AND AMONG GILEAD SCIENCES, INC., GRYPHON ACQUISITION SUB, INC., CORUS PHARMA, INC. AND RODNEY A. FERGUSON, PH.D, AS CHAIRMAN OF AND ON BEHALF OF THE STOCKHOLDER REPRESENTATIVE COMMITTEE DATED AS OF APRIL 12, 2006Agreement and Plan of Merger • November 6th, 2006 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
This Agreement and Plan of Merger (this “Agreement”) is made and entered into as of April 12, 2006, by and among GILEAD SCIENCES, INC., a Delaware corporation (“Acquiror”), GRYPHON ACQUISITION SUB, INC., a Delaware corporation and wholly owned subsidiary of Acquiror (“Merger Sub”), CORUS PHARMA, INC., a Delaware corporation (the “Company”) and RODNEY A. FERGUSON, PH.D., as Chairman of and on behalf of the Stockholder Representative Committee (the “Stockholder Representative Committee”).
